Private startupCompany profile · informational
Retro Biosciences
Retro Biosciences aims to extend healthy human lifespan through programs in autophagy, cell replacement and tissue reprogramming. Its lead oral drug, RTR242, entered a first-in-human Phase 1 trial, with Alzheimer's disease as a potential first indication.
Verified highlights each with its source
- Retro says RTR242, an oral therapy designed to restart autophagy, entered a Phase 1 clinical trial in 2025 (company blog, May 22, 2026).
Source: retro.bio ↗ - The first-in-human RTR242 trial is being run in Adelaide, Australia, initially in healthy volunteers (reported Dec. 30, 2025).
Source: longevity.technology ↗ - In May 2026 Retro announced an initial close of a new financing led by 4P Capital.
Source: retro.bio ↗
Sources
- retro.bioretro.bio
- statnews.comstatnews.com
Science and stocks are different questions. This profile describes scientific and regulatory progress. It says nothing about whether the company’s shares will rise or fall, and it is not a recommendation to buy, sell or hold any security.
Disclosure. Spin Pharma has no financial relationship with this company and holds no position in it.
